Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A £11 million Cancer Research UK investment has been awarded to the University of Oxford and Oxford-based NHS to catalyse the translation of its world-leading cancer research for patient benefit.

University of Oxford Skyline

The highly competitive Cancer Research UK Centre awards recognise the UK’s most innovative, high-impact cancer research and NHS-University collaborations. This coveted funding, announced today, will see £11 million invested in Oxford and the Thames Valley’s cancer research and translational infrastructure, and a further £3 million into training over the next 5 years.

Cancer remains the second largest cause of global mortality, impacting the lives of millions worldwide. Half of us will be diagnosed with cancer, and there is a strong demand for investment in academic excellence, and to support partnerships with industry and public health organisations.

Within Oxford, the funding will draw together academics and experts from across its fundamental, translational and clinical research communities including from cancer doctors, mathematicians, computer & data scientists, vaccinologists, immunologists, cellular biologists, drug discovery experts, clinical trialists, imaging experts and public health specialists. Nationally and internationally, the new investment will foster a multisectoral approach and invest partnerships that will deliver short and long term patient benefit.

Read the full story on the Oxford Cancer website. 

Similar stories

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.